381 related articles for article (PubMed ID: 23609386)
1. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.
Iyo M; Tadokoro S; Kanahara N; Hashimoto T; Niitsu T; Watanabe H; Hashimoto K
J Clin Psychopharmacol; 2013 Jun; 33(3):398-404. PubMed ID: 23609386
[TBL] [Abstract][Full Text] [Related]
2. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
3. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
Kimura H; Kanahara N; Sasaki T; Komatsu N; Ishige M; Muneoka K; Ino H; Yoshimura K; Yamanaka H; Suzuki T; Komatsu H; Watanabe H; Shimizu E; Iyo M
J Psychopharmacol; 2016 Aug; 30(8):795-802. PubMed ID: 27371496
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D2 receptors as treatment targets in schizophrenia.
Seeman P
Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.
Chouinard G; Samaha AN; Chouinard VA; Peretti CS; Kanahara N; Takase M; Iyo M
Psychother Psychosom; 2017; 86(4):189-219. PubMed ID: 28647739
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic-evoked dopamine supersensitivity.
Servonnet A; Samaha AN
Neuropharmacology; 2020 Feb; 163():107630. PubMed ID: 31077727
[TBL] [Abstract][Full Text] [Related]
7. Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia.
Oda Y; Kanahara N; Iyo M
Int J Mol Sci; 2015 Dec; 16(12):30144-63. PubMed ID: 26694375
[TBL] [Abstract][Full Text] [Related]
8. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
[TBL] [Abstract][Full Text] [Related]
9. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.
Nakata Y; Kanahara N; Iyo M
J Psychopharmacol; 2017 Dec; 31(12):1511-1518. PubMed ID: 28925317
[TBL] [Abstract][Full Text] [Related]
10. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis.
Kimura H; Kanahara N; Komatsu N; Ishige M; Muneoka K; Yoshimura M; Yamanaka H; Suzuki T; Komatsu H; Sasaki T; Hashimoto T; Hasegawa T; Shiina A; Ishikawa M; Sekine Y; Shiraishi T; Watanabe H; Shimizu E; Hashimoto K; Iyo M
Schizophr Res; 2014 May; 155(1-3):52-8. PubMed ID: 24667073
[TBL] [Abstract][Full Text] [Related]
11. Half a century of antipsychotics and still a central role for dopamine D2 receptors.
Kapur S; Mamo D
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1081-90. PubMed ID: 14642968
[TBL] [Abstract][Full Text] [Related]
12. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors.
Seeman P
CNS Neurosci Ther; 2011 Apr; 17(2):118-32. PubMed ID: 20560996
[TBL] [Abstract][Full Text] [Related]
13. Targeting the dopamine D2 receptor in schizophrenia.
Seeman P
Expert Opin Ther Targets; 2006 Aug; 10(4):515-31. PubMed ID: 16848689
[TBL] [Abstract][Full Text] [Related]
14. G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis.
Oda Y; Tadokoro S; Takase M; Kanahara N; Watanabe H; Shirayama Y; Hashimoto K; Iyo M
J Psychopharmacol; 2015 Dec; 29(12):1308-13. PubMed ID: 26174132
[TBL] [Abstract][Full Text] [Related]
15. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data.
Takeuchi H; Suzuki T; Bies RR; Remington G; Mamo DC; Pollock BG; Mimura M; Uchida H
Schizophr Res; 2013 Nov; 150(2-3):373-9. PubMed ID: 24028745
[TBL] [Abstract][Full Text] [Related]
16. Are dopamine D2 receptors out of control in psychosis?
Seeman P
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():146-52. PubMed ID: 23880595
[TBL] [Abstract][Full Text] [Related]
17. Role of dopamine D(2) receptors for antipsychotic activity.
Ginovart N; Kapur S
Handb Exp Pharmacol; 2012; (212):27-52. PubMed ID: 23129327
[TBL] [Abstract][Full Text] [Related]
18. Hypothetical dopamine dynamics in mania and psychosis--its pharmacokinetic implications.
Park SY; Kang UG
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():89-95. PubMed ID: 23268190
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Tadori Y; Kikuchi T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
[TBL] [Abstract][Full Text] [Related]
20. What are the optimal pharmacokinetic properties of antipsychotic medications?
Kang UG
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jan; 36(1):117-21. PubMed ID: 21896301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
